Fig 1.
Economic returns from academic and corporate licenses to biotechnology companies.
(a.) Effective royalty rate on $500M in net sales; (b.) Total reported deal size; (c.) Total precommercial payments. Analysis excludes licenses to pharmaceutical companies.
Table 1.
Economic returns for biotechnology licenses by licensor and licensee.
Fig 2.
Economic returns from academic-biotech, corporate-biotech, and corporate-pharma licenses by development phase of lead product.
Effective royalty rate on $500M in net sales for (a.) Academic-biotech licenses; (b.) Corporate-biotech licenses; and (c.) Corporate-pharma licenses. Deal size for (d.) Academic-biotech licenses; (e.) Corporate-biotech licenses; and (f.) Corporate-pharma licenses. Precommercial payments for (g.) Academic-biotech licenses; (h.) Corporate-biotech licenses; and (i.) Corporate-pharma licenses. Development phase is defined as the development phase of the most advanced product (discovery, lead molecule, preclinical, phase 1, phase 2, phase 3, or approved). Phase 3 trials are not included in data describing academic licenses due to insufficient data. Note differences in the scale for the deal size and precommercial payments of different license classes.
Table 2.
Economic returns for biotechnology licenses by license class and development phase.
Table 3.
Economic returns for biotechnology licenses by licensee and development phase.
Table 4.
Median regression coefficients by licensor, most advanced development phase and deal terms.